The traditional pharmaceutical order, once anchored in Western centres, has fundamentally shifted. We now inhabit a bipolar industry landscape dominated by the United States and China. This transformation carries significant implications for patients, investors, and policymakers worldwide. Chinese Pharmaceutical Innovation Drives Global Research Boom China has rapidly closed the gap in medical research. In several key areas, it has now…
Tag: healthcare industry
-
GLP-1 Weight Loss Medications Gain Traction In South Africa
South Africa is witnessing the early stages of a significant shift in the healthcare and consumer goods sectors. New data reveal that GLP-1 weight loss medications are beginning to gain a foothold in the local market. While global headlines have been dominated by brands like Ozempic, Wegovy, and Mounjaro, the South African landscape is currently defined by both high potential…
-
SA Professional Stress Index: A New Persistent Reality
A new study has revealed a troubling shift in the mental well-being of the nation’s workforce. According to the SA Professional Stress Index, conducted by Profmed, stress is no longer a series of isolated incidents. Instead, for over 4,000 surveyed professionals, it has become a “persistent, multilayered reality”. The report highlights a growing cohort of experts who spend prolonged periods…
-
Illegal weight loss injections: The rising black market crisis
The quest for rapid weight loss in South Africa has birthed a dangerous shadow economy. For many, acquiring potent GLP-1 agonists no longer requires a clinical consultation. Instead, it involves a few WhatsApp messages and a payment to a stranger. This burgeoning trade in illegal weight loss injections highlights a desperate intersection of public health needs and economic barriers. As…
-
Discovery Health Reports Profit Amid Shifting Membership Base
Discovery Health has reported a profit for the recent financial year. This positive result comes despite a slight dip in medical scheme members. The company shows strong financial performance overall. Its strategies are successfully adapting to market changes. This ensures continued profitability and stability. The financial outcome highlights a robust business model. Analysing Membership Trends The Discovery Health Medical Scheme…
-
Aspen Pharmacare Manufacturing Dispute Shrouded in Mystery
ASPEN Pharmacare has issued a stark warning to investors. They are signalling a potential R2 billion plunge in core earnings for its 2025 financial year. This is due to the significant Aspen Pharmacare manufacturing dispute detailed this week. In a regulatory filing on Tuesday, Aspen alerted shareholders to emerging risks. It highlighted a “material contractual dispute” with an unnamed contract…
-
Governance at Bonitas raises serious concerns
The growing unease surrounding the governance of Bonitas, South Africa’s second-largest medical scheme, continues to deepen. Recent responses from Bonitas and the Council for Medical Schemes (CMS) have done little to quell concerns about questionable practices. Instead of offering transparency, they appear to be dodging key allegations, leaving stakeholders with more questions than answers. Bonitas’s recent decisions, particularly regarding its…
-
CMS responds to Bonitas corruption allegations
The Council for Medical Schemes (CMS) has responded to Michael Avery’s recent column titled “Anatomy of a scandal: Bonitas said to have lost Sanlam’s trust” (October 14), which questioned the regulatory body’s oversight and raised concerns about long-standing contracts in the medical scheme industry. Avery’s article insinuated that the CMS has been passive as a regulator. However, the CMS pointed…